Andrew M. Berdon

Andrew M. Berdon is a partner in the New York office of Quinn Emanuel Urquhart & Sullivan with over 30 years of experience as a trial lawyer, focusing on patent litigation and other complex commercial disputes within the life sciences and pharmaceutical industries. His practice encompasses matters related to product development, licensing, and trade secrets. The authoritative case list shows him representing plaintiffs in Hatch-Waxman litigation, including Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc. and Veloxis Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd. His broader practice includes defending companies, such as representing Sarepta Therapeutics in a patent case concerning gene therapy treatment.

Mr. Berdon's career includes time as in-house general counsel for a multinational pharmaceutical company, providing him with a client-side perspective on litigation and industry practices. Prior to his current role at Quinn Emanuel, he represented Veloxis Pharmaceuticals while at Patterson Belknap Webb & Tyler. Beyond his patent-specific work, Mr. Berdon has secured significant outcomes in high-stakes commercial disputes. Notably, he was lead trial counsel for the selling shareholders of Syntimmune, Inc. in a post-merger dispute against Alexion Pharmaceuticals, obtaining a judgment of $130 million after a seven-day bench trial in Delaware Chancery Court.

While Mr. Berdon's practice is concentrated in district court litigation, there is no readily available information indicating a regular practice before the Patent Trial and Appeal Board (PTAB).

Mr. Berdon earned his J.D. from Albany Law School of Union University in 1987 and a B.A. from the University of Rochester in 1984. He is admitted to practice in New York.